Clinical Trial Update: The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study [NA]

View source ↗

Summary

A pilot clinical trial evaluating the SetPoint System as a pro-remyelination therapy for relapsing-remitting multiple sclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• SetPoint System

Snippet

Sponsor: SetPoint Medical Corporation | Conditions: Relapsing Remitting Multiple Sclerosis | NA | Status: RECRUITING